bioAffinity Technologies, Inc. (NASDAQ:BIAF) Sees Significant Decrease in Short Interest

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the recipient of a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 226,200 shares, a decline of 16.7% from the October 31st total of 271,400 shares. Based on an average trading volume of 123,400 shares, the days-to-cover ratio is currently 1.8 days. Currently, 2.4% of the shares of the company are short sold.

bioAffinity Technologies Stock Performance

BIAF traded up $0.05 during mid-day trading on Friday, reaching $1.22. 22,697 shares of the company traded hands, compared to its average volume of 138,038. The company’s fifty day moving average price is $1.56 and its 200-day moving average price is $1.89. The company has a quick ratio of 1.01, a current ratio of 1.02 and a debt-to-equity ratio of 0.18. bioAffinity Technologies has a 52-week low of $1.03 and a 52-week high of $3.62. The stock has a market capitalization of $18.94 million, a P/E ratio of -1.48 and a beta of 3.10.

Hedge Funds Weigh In On bioAffinity Technologies

A hedge fund recently bought a new stake in bioAffinity Technologies stock. Ground Swell Capital LLC purchased a new stake in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 22,864 shares of the company’s stock, valued at approximately $49,000. Ground Swell Capital LLC owned about 0.20% of bioAffinity Technologies at the end of the most recent quarter. 1.64% of the stock is currently owned by institutional investors and hedge funds.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.